Green Cross Corporation, a South Korean biopharmaceutical company, announced today that South Korea's Ministry of Food and Drug Safety has approved GCFLU QUADRIVALENT (Influenza Virus Vaccine) for immunisation of adults to help prevent disease caused by seasonal influenza (flu) virus subtype A and B. GCFlu Quadrivalent is the first locally-manufactured vaccine to cover against four influenza strains.
Until recent years, seasonal flu vaccines included two A virus strains and only one B strain. GCFlu Quadrivalent adds coverage a second B strain to help protect against flu disease.
"Green Cross is committed to providing new immunization option for the protection of flu, and we are excited to introduce GCFlu Quadrivalent as an important newest addition to the GCFlu which is administered to more than 100 million people in the world last 5 years," said EC Huh, Ph. D., President of Green Cross Corporation.
GCFlu Quadrivalent will be available to the healthcare providers in South Korea for the 2016-2017 flu season in prefilled syringes for intramuscular administration.
About Seasonal Influenza
Seasonal influenza may cause three to five million cases of severe illness and up to 500,000 deaths per year worldwide. Vaccination against influenza is considered one of the most effective ways of preventing mortality, complications and hospitalisations.
About Green Cross Corporation
Green Cross Corporation (Green Cross) is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in South Korea, Green Cross is the largest plasma protein product manufacturer in Asia and has been dedicated to quality healthcare solutions for nearly half a century.
This release includes forward-looking statements, which express the current beliefs and expectations of management. Such statements speak only as of the date on which they are made and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.